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Terms of reference
To advise on the acceptability of the use of Carotenes
Chlorophylls (E1a0) and Anthocyanins  (E163) in foods for
for young children  aged l-3 years.
(E 160a), Beetroot red (E,162),
special medical purposes (FSMP)
Background
According to Council Directive gll3zllBc, "infants" means those below 12 months of age and
"young children" those between 12 and 36 months of age (1). The use of additives in FSMP
for infants and young children is controlled  under Part 4 of Annex VI of the European
Parliament and Council Directive 9512/EC on food additives other than colours and
sweeteners  (2) This restricts  the additives permitted in FSMP to those listed in Parts 1-3 of
Annex VI to this same Directive which cover additives permitted  in infant formulae,  follow-on
formulae and weaning foods for children in good health. None of these permitted pdditives
are colours. Annex II of European Parliament and Council Directive 94136/EC  on colours  for
use in foodstuffs (3) lists foods for infants and young children including those not in good
health as one of the categories of foodstuffs which may not contain  added colours. The four
colours requested are however all permitted at quantum satis levels in foodstuffs  generally,
other than those foodstuffs listed in the colours Directive as having restrictions.
General considerations
In considering the request  to use four colours in FSMP for young children, the Comrnittee was
mindful of the principle set out in its earlier reports that it is prudent to keep the number of
additives used in foods for infants and young children to the minimum necessary (4, 5). The
Committee continues to endorse this principle, but has also acknowledged  earlier that
nutritional adequacy  requires that food be palatable to children (4). In this context,  the
Comrnittee  considered that the use of colours in FSMP for young children could represent  a
special  case.
The Committee noted that for some young children FSMP will form the major source of
nutrients and that it is important to ensure that there is good compliance with these strictly
controlled diets. The roles which added colours  and flavours may play in the acceptability  and
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palatability of FSMP, which would otherwise generally  be rather bland, is difficult for the
Committee  to judge.
The Committee  was presented  with limited evidence from acceptability  trials (6). Thirty-three
children (age not stated) suffering from a variety of conditions  and receiving  different FSMP in
UK hospitals were given first uncoloured, unflavoured products for a short period.
Compliance ranged from 0-11%. They were then given equivalent  coloured, flavoured
products and compliance  improved to 79-100o/o. Two other studies in France and the UK
have investigated  long-term  compliance  with coloured, flavoured products in children  aged
from 2 years upwards who had been showing poor compliance with diets containing
uncoloured,  unflavoured  products. In both studies product  acceptability  and long-term
compliance improved. The Committee  notes these findings and the fact that there is
laboratory  evidence  that colour plays an important role in determining the perception  of
flavour  and the acceptability  of foods in general (6, 9). However,  no acceptability trials on
FSMP have been presented  which examine separately  the roles of added colour and of added
flavour. The Committee is further  unable to judge whether colours are required to ensure
good compliance from as young as 12 months of age.
FSMP are intended for use for a very heterogeneous  group of medical conditions  and it should
be noted that the views on safety which the Committee  offers in this opinion can only be based
on general considerations rather than considerations of the precise nature of the various
illnesses and conditions  for which thev are intended for use.
Relevant existing Scientific Committee  for Food (SCF) opinions
These colours  have all been considered by the SCF in 1975 (7) and deemed either acceptable
without establishing an Acceptable Daily Intake (ADD or, in the case of beta-carotene,  an ADI
has been established,  The SCF views from 1975 mav be summarised  as follows:-
Carotenes
Beetroot red
Chlorophylls
8160a(i)
E160a(ii)
El62
E'140
mixed carotenes from natural
acceptable  for food use generally
synthetic beta-carotene:  ADI
bodyrreight
acceptable  for food use generally
chlorophylls and chlorophyllins
natural sources:  acceptable
generally
food sources:
of 0-5 me/ke
obtained from
for  food use
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Anthocvanins E163
Intake considerations
The rnaximum levels of use requested
consumed are as follows:-
anthocyanins  prepared by physical  processes
from natural foods: acceptable for food use
generally
for these colours in FSMP in dilute products as
30 mg/L
20 mglL
Carotenes
Beetroot red
Chlorophylls
Anthocyanins
E160a
F.l62
E140  2O mslL
El63 20 mglL
Utilising the maximum  levels of use requested and the recommended energy intake and fluid
requirements for 1-3 year-olds,  the maximum  intake of each colour would be about 3 mglkg
bodyrveight/day  for Carotenes, and about Z mglkg bodyweight/day for each of Beetroot  red,
Chlorophylls and Anthocyanins.  These  estimates  may be compared with estimates of intakes
of these colours  from all sources  by normal children  aged 1.5 - 4.5 years of age, derived from
the British National  Diet and Nutrition Survey, in which the 97.5th percentile intakes were
estimated as 0.9. 1.3, 3.2 and 3.7 mglkg bodyweight/day  for Carotenes, Beetroot  red,
Chlorophylls  and Anthocyanins respectively (8). Thus the estimated maxirnum intakes of
colours for children  consuming FSMP would not be significantly  greater than the estimates  for
normal children for Carotenes and Beetroot red and lesser for Chlorophylls and Anthocyanins.
The Committee notes that typical levels of use of colour in FSMP is around 10 mgil rather
than the rnaximum levels requested.
Toxicological  considerations
Given these four colours have all been deemed acceptable for food use generally,  the
additional  relevant safety consideration  for the use of colours  in FSMP is whether  there is any
likelihood that young children with particular medical conditions might react to these colours
differently from normal children and adults. With the exception of children suffering from
allergy to cow's milk or other whole proteins, who may be at higher risk of intolerance to
other dietary constituents,  there is no evidence  to suggest that children requiring FSMP would
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be more likely to experience adverse effects from these colours. The Cornmittee also notes
that these colours  have been found to exhibit no or very low toxicity in studies incorporating
high doses into the feed of rats, mice and dogs.
Beta-carotene
The applicants in different parts of the submissions  (6, 9) have requested  use of Carotenes and
Beta-carotene. Beta-carotene  has been administered  in doses up to  1000 mdkg
bodyweighVday in sub-chronic, long-term,  multigeneration and teratogenicity  studies with
minimal or no effects. It is negative in in vitro and in vivo mutagenicity studies (10, 1l).
Earlier literature on Beta-carotene  suggested that is poorly absorbed  unless given in oil (10).
Some is stored in the liver and epithelial tissue. Some is converted to vitamin A and stored in
the liver as vitamin A. Absorption of Beta-carotene  has been quoted as lower in babies
(2 6%) than in adults (11%) and conversion of Beta-carotene to vitarnin A is said to be
reduced in gastrointestinal,  liver and kidney disease (12). However, there may be considerable
individual variation in the absorption  of Beta-carotene  and in the extent of its transformation
to vitamin A (13, 14)  These and other aspects of synthetic Beta-carotene  are being
considered  separately by the Committee. The Committee therefore  considers that Mixed
carotenes derived from natural foods normally consumed are acceptable for use in FSMP, but
that until the separate review of Beta-carotene is completed, the Committee  is unable to give a
view on the use of svnthetic Beta-carotene in FSMP.
Beetroot red
The major colouring principle  of Beetroot red, betanine, has been reviewed by the SCF and by
the FAOAVHO Joint Expert Committee on Food Additives  (JECFA) (7, 15) It is poorly
absorbed in the rat and mostly metabolised in the gastro-intestinal  tract. Betanine was not
carcinogenic when given to rats at 50-78 mdkg bw/day in the drinking water or via
subcutaneous injection. Neither did four different  preparations  of beet pigment initiate or
promote  hepato-carcinogenesis  when given with N-nitrosodiethylamine. Beet red was not
mutagenic in in vitro tests. JECFA considered  an important safety consideration was to
control the nitrate component of beet red via its specification  because there was a need to limit
nitrate in foods produced for infants and young children (16). The Committee  notes that such
a limitation would be necessary whether or not infants were in good health. The EU
specification (Commission Directive 95/36/EC)  limits nitrate to not more than 29 nitrate
anion/g of red colour (17)
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Chlorophyll
Chlorophylls are obtained by solvent  extraction of grass or lucerne. The colour requested (E
140) refers to chlorophylls and chlorophyllins obtained from natural sources. In 1975, the
SCF noted that no biological data were available for natural chlorophylls and did not establish
an ADI but agreed  that their use in food generally was acceptable (7). The Committee notes
that in 1975 only chlorophylls  obtained by physical processes from natural food sources
normally consumed were discussed, whereas under the current EU Directive on colours, (3)
chlorophylls frorn non-human food sources  (e.g. grass)  are allowed.
Anthocyanins
Anthocyanins represent  a large group of 200 or more water-soluble plant pigments which
occur naturally in a wide range of fruits and vegetables.  They normally exist as glycosides,
chemically  combined to a sugar moiety (glucose, rhamnose, galactose, xylose and arabinose).
In 1975, the SCF noted that no biological data were available and did not establish an ADI,
but anthocyanins prepared by physical processes  from natural foods were regarded as
acceptable  for use in food without further investigations  (7).
Anthocyanins appear to be poorly absorbed from the gastro-intestinal tract in rats, dogs,
rabbits and man, and do not appear to be metabolised.  The coloured parent compounds  are
not found in human urine as measured  by the comparatively  insensitive test of colouration. In
rats, some anthocyanins may be degraded by bacteria in the gut and their breakdown products
(mostly  unidentified) absorbed to a limited extent (15).
No effects  have been observed in subchronic  studies in rats, guinea pigs and dogs, nor in a
multigeneration reproduction study in rats in which anthocyanin  or grape-skin extracts were
given up to high doses in the diet (15). Anthocyanin extracts  were not teratogenic in rnice,
rats or rabbits and were not rnutagenic in in vitro tests (15).
Two of the most common anthocyanins,  pelargonidin and delphinidin have been shown to
inhibit aldoreductase  in the lens of rats. Other anthocyanins  extracted from grapes were
shown to increase the activity of of alpha-glucan  phosphorylase  and glutamic acid
decarboxylase,  but inhibit glycerol dehydrogenase, rnalate  dehydrogenase  and hexokinase.
The Committee notes that it is perhaps possible that these interactions with enzymes could
have an effect in certain inborn errors of carbohydrate metabolism.15
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Conclusions
Where toxicological  data exist, it can be seen that the intrinsic toxicity of the four colours
requested  is extremely low. It has been estimated  that extreme intakes of these four colours in
FSMP by young children with medical conditions would be comparable to or less than those of
normal children who are high consumers  of foods containing these colours  naturally.
Considering the question of whether  any of these colours may pose special problems if present
in FSMP because of the nature of the medical conditions of the children consuming  them,
there does not appear to be any obvious cause for concern from the information  available.
Although  the biological information is limited, it is not anticipated that conditions  such as
inborn errors of metabolism, intestinal,  liver or kidney disease, or general feeding difficulties,
would predispose to problems with the use of any of these four colours. Only in the case of
allergy might there be a predisposition to intolerance to colours (18). The Committee
therefore  considers  that use of colours  may be inadvisable in products for children with cows'
milk or other protein allergies.
It is noted that there has already been considerable experience of the use of FSMP to which
these colours have been added in young children whilst under close medical supervision  and
observation.  FSMP can form the major part of their diet and no untoward effects have been
attributed  to the presence of colours in FSMP to date.
The Committee  concludes that mixed carotenes, beetroot red, chlorophylls and anthocyanins
are acceptable from the safety point of view for use in FSMP for young children frorn 12
months of age upwards, up to the maximum levels requested in the diluted product as
consumed (mixed carotenes 30 mg/L, chlorophyll 20 mglL, beetroot red 20 mg/L and
anthocyanins 20 mg/L).
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(expressed  on 13 December 1996)
2.
Mandate
To advise on the maximurn levels, where necessary, for vitamins,  minerals, trace elements and
other nutritional  substances added to processed  cereal-based  foods and baby foods.
Regulatory situation
l. In conformity with the provisions  of article 5 of Commission  Directive 961SlEC  of l6
February  1996 on processed cereal-based foods and baby foods, only the vitamins,
minerals,  trace elernents, amino acids and other nitrogen containing compounts  listed
in Annex IV of the directive  may be used in the manufacturing  of these products [].
The only specifications with respect to these substances to be found in Annex I (cereal
based foods) and Annex II (baby foods) of the directive  concern sodium, calcium,
thiamin, vitamin C, vitamin A and vitamin D. Minimum values are stipulated for
calcium in products mentioned  in articles  t (Z)(a)(ii) (cereals which are to be
reconstituted with water) and 1(2)(a)(iv) (milk biscuits), for thiamin in processed
cereal-based  products,  for vitamin C in fruit juices, nectars or vegetable  juices, and for
vitarnin  A in vegetable  juices. Maximum limits are set for sodium in cereal-based  foods
and baby foods. Minimum  and maximum limits, identical to those for follow-on
formulae (Directive gll32llEEc),  are provided for vitamins A and D in cereal-based
foods (the addition of vitamin D in baby foods is not permitted). Further, it is stressed
that the addition of amino acids is only allowed to improve the nutritional value of the
protein mixtures  and only in quantities necessary for that purpose (point 2 4 of annex I
and point 1 .5 of annex II).
General principles
Maxirnal values, when needed, should be fixed on the basis of two sets of
considerations  : 1) toxicological reasons when a demonstrated threshold  of toxicity has
been defined ;2) and nutritional balance  taking into account the paucity of knowledge
about the long-term effects of chronic exposure to supra-physiogical  intakes in infants
and young children. Thus, an upper lirnit may be fixed for all added vitamins  and
minerals, even for the apparently non-toxic ones, or those whose toxicity appears to be
extremely  low. Indeed, it seems an equitable principle  that if a specific nutrient  is added
3.
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to a food, rather than being naturally present in the food, then a maximum should be
set [2].
Data in food composition tables normally reflects  the average statistical values rather
than the true content. Baby foods are very often a combination of different types of
food (for example,  beef, carrots and potatoes).  This variability leads to the large range
of variations  within the nutrient content.  The usual calculation of the nutrient content,
based on recipes, only provides rough information.  Processing  (e.g. heat treatment),
other factors like pH, presence or absence of reactive  elements (such as iron or
copper),  and storage conditions  are further contributory factors. Moreover, the amount
added should garantie that the declared amount of the nutrient, mainly vitamins, is still
present on expiry of the minimurn shelf life.
In assessing  the maximum value, we have to consider that it is very improbable  that the
intake of baby foods by infants over the age of 4 months and young children  (1-3
years) would exceed 6 jars of 200 g per day (i.e. 850 kcal/d based on an average
energy content ofabout 70 kcal/l00 g) [3]
Water-soluble  vitamins
When the amount of a water-soluble  vitamin consumed is greater than the required by
the body, the excess is excreted. This explains why their toxicity generally is low and
that informations  available  in adults suggest that the ratio between PRI and toxic levels
is about 100 (Table I). However, no long-term  exposure data are available for small
babies, and it has been suggested that a reasonable cautious upper limit for infants
should be set not higher than 5 times the present  US RDAs [a].
Possible exceptions are thiamin,  niacin and vitamin 86 for which it has bee suggested
that maxirnum levels in baby foods ready for consumption  should not exceed 4 times,  2
times and 5 times respectively  the EC Population Reference Intake (PRI) fbr infants
per 100 g.Based on a consumption  of 6 jars of 200 g per day containing such levels
the daily intake of these three vitamins would not exceed one tenth of doses, as
extrapolated from the adult to 4 month infants, suspected to have toxic effects if
ingested over a long period t3l
Vitamin C could also be a matter of concern if added in very large quantities in baby
foods. There also it has been suggested  that vitamin C levels should not exceed twice
5.
6
8.
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the PRI per 100 g of solid foods and4 times for fruit/vegetable  juices, since the total
amount ofjuice consumed is likely to be less than the amount of solids [3].
The toxicity risk of adding water soluble vitamins to baby foods and processed cereal-
based foods for infants and young children is negligible. However setting maximum
limits is prudent for nutritional considerations  and we recommend the nutrient density
of the water-soluble  vitamins  in baby's foods, expressed for 100 kcal of foods as ready
for use, does not exceed about 50 o  of the EC PRI for young children, i.e.
approximately  one half of the references  values for nutrition labelling  (annex V) of the
directive 9615/EC. The same reasoning  should apply to biotin and pantothenic acid
although no PRI has been established for them ; the upper limit should be inspired in
these cases by the safe and adequate  daily intakes for 1-3 year-old children suggested
by the Food and Nutrition Board [5], i.e. 20 pgand 3 mg, respectively  (Table II).
An exception  should however be made for thiamin in cereals, for vitamin C in products
enriched with iron, and for vitamin C in fruit juices, nectars and vegetable  juices.
Article 6.1 of annex I of directive  9615lF;C stipulates that the amount of thiamin shall
not be less than 100 pg per 100 kcal for processed  cereal-based foods ; it seems
therefore reasonable in this case that the maximum  limit does not exceed 5 tirnes the
minimum, i.e. 0. 5 mgllOO kcal. As for vitamin C, article 5 of annex II of the above
mentioned directive provides that in fruit juices and nectars and vegetable juices the
content  should not be less than 25 mg per 100 g or per 100 kcal, that is 100 % of
the PRI for this age group ; given the relatively low consumption  of these products
by infants and young children a maximum value of 125 mg per 100 kcal could be
recornmended. We have also to take into consideration  the fact that iron absorption  is
improved  by ascorbic acid; it is therefore necessary to set the maximum vitamin C level
in such a way that optimum iron absorption is possible, which justify a maximum of 25
mg/100 kcal in products fortified with iron. The same vitamin C maximum of 25
me/I00 kcal also could be allowed for fruit-based  dishes (Table II).
Fat-soluble  vitamins
Maximum  levels of vitamins A and D (180 pg RE and 3 pg cholecalciferol,
respeotively,  per 100 kcal) that may be added to processed cereal-based  foods which
have to be reconstituded  with milk of other appropriate nutritious  liquids are already
covered in the 96/5/EC directive. These limits are also applicable if vitarnins  A and D
are added to other processed  cereal-based  foods. Vitamins A and D may not be added
to other baby foods, the only exception being vegetable juices, in which the final
10.
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content of vitamin A in the product should be not less than 100 pg RE per 100 kcal
t1l
Regular daily intakes of retinol should not exceed 900 pelday in 6-12 months old
infants and 1800 pglday in children aged 1-3 years [6]. Vitarnin A naturally present in
vegetable  juices is as carotenoids. An appropriate  maximum  for the amount of retinol
added to vegetable  juices, as suggested by the UK IDFA, whould be 90 pg/l00 rnl as
consumed  (one tenth of the maximum retinol intake per 100 ml). Infants with very high
intakes of such juices, and consuming  some retinol from other sources,  should
therefore be unlikely to exceed a total retinol of 900 ltglday [3]. The Comrnittee  agrees
with this approach but suggests that the upper limit for vitamin A in vegetable juices
should be set at the same level as for infant formulae and follow-on formulae"  i.e. 180
pg RE per 100 kcal.
Vitamin E per os is practically not toxic. Few adverse  effects were reported and none
consistently.  Most adults appear to tolerate doses of 200 to 600 mglday, without
evidence of toxicity. Some adults complain of gastrointestinal  disturbances (diarrhoea
and cramps) and interference  with anticoagulation therapy has been reported [7,8].
Nevertheless,  vitamine E supplementation  is not generaly  encouraged  [5] and it has
been recommended to limit the amount of vitamin E added to infant foods [9]. It is
therefore more safe to set a maximum  value for vitamin E in processed cereal-based
foods and other baby foods. Under the circumstances  the Committee  recommends that
the vitamin E content does not exceed half the NASA{RC RDA, i.e. 3 mg a-TE per
100 kcal of the product  ready to eat (Table II).
The situation  is less clear with respect to vitamin K. "Recommended intakes"  are set at
5 pglday for the first 6 months, at 10 pilday for the following 6months and at 15
Vilday between  1 and 3 years [5] A minimum of 4 pg/100 kcal has been suggested  for
infant formulae , adopted by the Codex Alimentarius [CODEX STAIN 72-1981] and
specified in directive 91/321|EEC on infant formulae and follow-on formulae. On the
other hand, the COMA and the SCF considered  that they had not enough data to make
a recommendation but that an intake of I pg/kg body weight per day appears  adequate
and would be provided by a normal mixed diet [6]. Since no adverse  sign has ever been
reported  from large oral doses of vitamin K, the Committee sees no reason to make a
recommandation.
13.
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Minerals and trace elements
Calcium excess arising from dietary intakes is rare because  of the effectiveness of the
homeostatic  mechanisms.  In healthy adults intakes of 2.5 g are well tolerated  but above
this, as may occur after ingestion of supplements  of calcium (and sometimes of
vitamins) or of antacids there is a risk of renal stones, hypercalcaemia  and impaired
renal function. An upper limit of intake 2 5 gld has been therefore advised,  i.e.
approximately  3-4 times the PRI for adult men [6]. Minimum values for calcium
content of complete cereals to be reconstituted  with water and milk biscuits have been
set to 80 mg and 50 mg/100 kcal, respectively,  in the above mentioned Directive. Even
if there is little evidence of toxic effects of high calcium  intakes in infants and young
children, the Committee recommend that the calcium  content of cereals which are to
be reconstituted with water and milk biscuits does not exceed twice the minimum
values required by the Directive,  i.e. 160 and 100 mg/100 kcal, respectively. On the
other hand, when calcium is added to other processed cereal-based products and to
baby foods, which are not usually an important source of calcium for infants and young
children,  the Committee  recommends  that, if calciurn is added, the total calcium
content  does not exceed one fifth the PRI for 1-3 year- old children i.e. 80 mg/l00 kcal
of the product as sold.
The very effective regulation of iron absorption prevents  overload of the tissues by
iron from a normal diet, except in individuals genetically susceptible (e.g. idiopathic
haernochromatosis)  [6] The acute toxic dose in infants and young children has been
estimated to approximately 2A mglkg body weight and the lethal dose to about 200-
300 mg ferrous iron/kg body weight. This gives an acute toxic dose of about 10-20
times the PRI for 1-3 year-old children (4 mgld, assuming  a bioavailability of iron frorn
all the diet of 15 %). Nevertheless infants and young children  normally receive already
iron-fortified foods (e.g. infant and follow-on formulae). It is therefore appropriate  to
set a maximum level for the iron content of weaning foods [3]. Taking into account the
fact that the absorbability of iron in weaning foods is probably lower than 15 oA,
possibly  down to 10 Vo or even less if ferric salts are used, an upper limit of 15 oh the
PR[, i.e. 3 mgl100 kcal of the ready to eat product is advised.
Magnesium  is ubiquitous in the diet ; both plants and meats are good dietary souroe$.
Additionally  the improved efiiciency, on restricted intakes, of both intestinal  absorption
and renal conservation  of magnesium has made it difficult for the SCF to propose  any
PRI with confidence.  An acceptable range of intakes of 150-500 mgd was therefore
proposed.  The difficulties in proposing a reliable PRI for adults are more pronounced
in children for whom data are even more scarce. However, the quasi-PRl for the 1-3
16
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year-old children, calculated  on the basis of body weight,  has been estimated by the
Committee to 85 mg/d [6], a value which does not really differ from the NASA{RC
RDA for the same age group, i.e. 80 mg/d [5]. Since there is no evidence that large
dietary  intakes are harmful to humans with normal renal function, except for the
induction of intestinal secretion  and diarrhoea  with amounts  exceeding l0 times the
acceptable range of intakes for adults, an upper limit of 50 % the present NASAIRC
RDA of 1-3 year-old-children,  i.e. 40 rng/l00 kcal, could be set [3].
A sirnilar opinion can be adopted for manganese since manganese is particularly
abundant  in vegetable-based  foods. If a manganese salt is added, however, in harmony
with our general approach, it would be safe to set as upper lirnit 50 9/o of the
NASA{RC "estimated safe and adequate  daily dietary intake" of l-3 year-old-children,
i.e. 0.6 mg/I00 kcal.
A PRI of about 3 gld has been proposed for potassium by the SCF and PRIs for ages
up to 17 were estimated factorially  (800 mg/d for 1-3 year-old  children). In adults
intakes of 17.5 g/d may induce symptomatic  hyperkalaemia in some otherwise normal
individuals. However,  intakes above 6 g/d could be dangerous  for individuals  with
undetected  renal dysfunction. Since there is no apparent  benefit of exceeding such
intakes, this has bee proposed  as an upper safe level of intake [6]. Since the safe level
of intake in adults is only twice the PR[, the Committee  recommends to set an upper
limit for potassium when it is added to weaning foods. This upper limit, if potassium is
added, could be set to one fifth the PRI of l-3 year-old children, i.e. 160 mgl100 kcal
of the product as sold.
High intakes of copper are toxic. The PRI for adults has been set by the Committee to
1 I mgld and for safety reasons  an upper lmit of 10 mg/d has been proposed.  The PRI
for children has been calculated factorially, the value for 1-3 year-old children  being set
to 0.4 mgld [6]. Daily intakes of copper for infants are 0.3-0.6 mg/d ; intakes for rnost
infants should therefore be satisfactory,  and fortification  of weaning foods with copper
is not only unnecessary, but is also inadvisable [3] For all these reasons, the
Committee  recommends to limit strictly the addition of copper to weaning Ibods and
to set an upper limit which not exceed  one tenth the PRI of 1-3 year-old children, i.e.
40 pg/100 kcal ofthe ready to eat product.
Gross acute zinc toxicity  has been described  following  the use of water which has been
stored in galvanised containers. Prolonged  intakes of 75-300 mg/d in adults have been
associated with impaired copper utilisation, producing  features such as microcytic
anaemia and neutropenia, but even short term intakes of about 50 mg zinc daily
interfere with the metabolism of both iron and copper. The PRI for zinc has been set to
20.
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9.5 mgld but, to avoid interactions  with iron and copper, the Committee has
considered that it would be unwise to exceed a daily zinc intake of 30 mg in adults, i e.
three times the PRI. The PRI for l-3 year-old children  calculated factorially is 4 mg/d,
a value possibly  over generous [6]. In the absence of data on toxicity in infants, if the
data for adults are extrapolated to infants and young children, then it would be
appropriate  to set a maximum  for the zinc content of savoury weaning foodsl to 50 o/o
the PRI, i.e.2 mgl100 kcal of the ready to eat product.
High iodine intakes  cause toxic nodular goitre and hyperthyoidism. Such toxicity  is
rare in normal populations  or individuals with an intake less than 5 mg/d but those with
pre-existent  iodine deficiency  may be susceptible to developing  toxic goitre at intakes
below this. The SCF has set the PRI for iodine to 130 pgld and intakes of I-2 mgld,
i.e. 10 times the PRI, appear to be safe in adults. PRI for 1-3 year-old children,
calculated from adult values on the basis of energy requirements,  is 70 pg/d. The
maximum limit for iodine in weaning foods should therefore be set to one half the PRI,
i.e. 35 pg/100 kcal of ready to use products  (Table III)
Other cornpounds
Carnitine, choline and inositol are listed in Annex IV, 3 of the Directive 96/5/EC.
Indeed it has been suggested that newborn infants, especially  the low-birth-weight
infants, may have insufficient biosynthetic capacity to produce their full requirement.
There is however no indication of any need for these compounds to be supplied
in the diet of healthy individuals  above the age of six months [6]) and no RDA can be
established [5]. On the other side, there is no evidence of toxicity and no untoward
effects after supplementation  have been reported so far in humans. It seems therefore
unnecessary  to set an upper limit for these three compounds.
Vitamins  and rninerals in foods for infants and young children
24 According to the informations provided by the Association of the Food Industries for
Particular  Nutritional  Uses of the European Union (IDACE), the practices of the
industry regarding cereal-based foods and baby foods in the European Union are
summarised  below (IDACE, 951647,18  Septernber 1995).
1  According  to the UK IFDA, addition of zinc to desserUnon savoury baby foods is inappropriate [3].
23
of the Scientific Committee  for Food (Fofiy-X'irst  Series)13 DECEMBER  1996 MAXIMUM LIMITS F'OR VITAMINS  AND MINERALS IN
PROCESSED  CEREAL-BASED T'OODS AND BABY
FOODS
25.
26.
In the various Member States, the manufacturers  tend to add a full range of vitamins
and minerals to milk-based  baby cereals. The rationale for these fortifications is that
milk-based baby cereals  are frequently  used as early weaning  foods when the diet first
becomes diversified. Manufacturers try to provide a certain amount of vitarnins and
rninerals to give similar levels of nutrients to those found in a milk-only diet (breast
milk or infant formula).
Simple cereals, rusks and biscuits, and/or baby pasta are often, but not always fortified.
In most European countries simple cereals are reconstituted  with milk and are fortified
with water-soluble  vitamins  (sometimes also with the fat-soluble  vitamins A, D and E)
and iron. Calcium is not often added. In Germany iodine is added due to paediatric
recommendations.  In Italy, on the contrary, simple cereals are generally  reconstituted
with a nutritious liquid, like a pure meat baby-food and water, to prepare a savoury
dish. They are supplemented with calcium, but iron is not usually added. Baby pastas
are practically only sold on the Italian market ; they have the same nutritional
properties as simple cereals, but a different physical structure ; the fortification  is
similar to that of simple cereals and generally includes vitamins of the B group, calcium
and iron. Rusks and biscuits can be compared with simple cereals (they are generally
consumed as an accompaniment to a milk-based  meal) and are usually fortified with
vitamins of the B group and sometimes  calcium and iron.
Savoury meals/dishes  are the most important category  of baby foods because they are
the basis of the baby's diet. Generally  they are not supplemented with vitamins  and
minerals, although  a few are fortified with iron. Fruit-based  products  (fruit-only dishes,
fruit juices and nectars) are all supplemented  with vitamin C. Vegetable dishes
sometimes contain high amounts of carotene from vegetable sources, and are
supplernented  in few cases with vitamin C, calcium and iron.
Vitarnins and minerals are supplemented both in order to restore the natural content
lost in the manufacturing  process and to guarantee a minimum vitamin content at the
end of the products life. A survey of compositional data, provided by the
manufacturers  (March 1996), is reassuring in indicating that, with few exceptions,  the
vitamin and mineral contents of products as consumed  do not exceed the proposed
maximum limits.
27
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Table I.  Relative toxicity  of water-soluble  vitamins in adult [from 6].
RDAI  PRI 2  Toxicity
Thiamin (mg)  1.5  1.1  No evidence of toxicity of thiamin taken
by mouth, at intakes up to 500 mg/day
(for I month)
Riboflavin (mg)  7.7  1.6  No evidence of any toxicity of B2 taken
by mouth
Niacin(mgNE)  19  18  Nicotinic acid, but not nicotinamide,  at
doses of 500 mglday,  may result in liver
damage
Vit 86 (mg)  2  1.5  Intakes of more than 50 mg/day must be
regarded as potentially harmful
Folate (prg)  200  200  Up to 5 rng per day would seem to be
well tolerated
Vit BtZ (pS)  2  7.4  A daily intake greater than 200 pg
should be discourased
Vit C (mg)  60  45  Up to 10 g/day ,;-  not to be unsafe
for healthy individuals
I for male s 25 - 50 yrs
2 for males  1g+ yrs
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Table II.  Maximum timits for vitamins, if added, in cereal-based foods and baby
foods for infants and young children.
Labelling
reference  value I
Maximum
per 100 kcal
Vitamin A (pg RE)
Vitamin E (mg a-TE)
Vitamin K (pe)
Vitamin C (mg)
Thiamin (mg)
Riboflavin (mg)
Niacin (mg NE)
Vitamin BO (mg)
Folate (pg)
VitaminBtZ (pg)
Pantothenic  acid (mg)
Biotin (pg)
400
62
752
25
0.5
0.8
9
0.7
100
0.7
33
203
180 4
3
NS5
ns6Q2r7
0 2s(0 s) I
4.4
4.5
0.35
50
0.35
1.5
10
I Annex V of the directive 96l5lEC
2 Recommended Dietary Allowances [5]
3 Saf. and adequate  daily intake [5]
4 Maximum value for vegetable juices
5 XS : not specified
6 Except for fruit-based dishes and for products fortified with iron for which the maxirnum
should be 25 rnglI00 kcal
7 Maximum value for fruit juices, nectars  and vegetable  juices, in parentheses
8 Maxirnum value for cereal-based  foods, in parentheses
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Table III.  Maximum limits for minerals and trace elements, if added, in cereals-
based foods and baby foods for infants and young children.
Labelling
reference  value  1
Maximum
per 100 kcal
Potassium (mg)  800 2  160
Calcium (mg)  400  80(160/100)  3
Magnesium (mg)  85 2  40
Iron (mg)  4  3
Zinc (mg)  4  2
Copper (pg)  400  40
Iodine (pg)  70  35
Manganese (mg)  NS 4  0.6
I Annex V of the directive  g6l5/EC
2 PRI for 1-3 year-old  children [6]
3 Maximum  values for products  mentioned in article f(Z)(a)(i) and (iv), respectively,  in
parentheses
4 NS : non specified
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coNSUMprroN  oF GEr{ETrcALLy  MODnUED MArZE (ZEA MAYS L)
(Opinion  expressed on 13 December 1996)
Terms of Reference
To consider whether  there is reason to believe that the genetic rnodification of the maize lines
of Zea mays L. will have adverse  effects on the health of human consumers of the maize. The
Committee is asked to give particular  attention to the concerns  raised by certain Member
States with respect to any potential toxic or allergenic  effects associated with the introduced
genes and any potential adverse effects from the non-expressed p-lactamase gene.
Background
The Commission  has submitted a proposal for a Council Decision concerning  the placing on
the market of genetically  modified maize (Zea mays L.) with the combined  modification  for
insecticidal properties  conferred by the Bt-endotoxin gene and increased  tolerance to the
herbicide glufosinate  ammonium pursuant to Council Directive 90/220/EEC.
Member States have expressed a variety of concerns  which have led the Commission to
request  the opinions  of the Scientific  Committee  for Food, the Scientific  Committee  on Animal
Nutrition (SCAN) and the Scientific Committee on Pesticides to examine the dossier as
concerns safety matters within their remits.
Evaluation
This evaluation  addresses transgenic maize CG-00526-176.  The submission  included the
administrative  data necessary for its unique identification and for record keeping purposes.
1. Characterisation  of the inserted  genes and their expression
On the basis of the information provided,  the inserted genos (CRYIA(b),  bar and bla) and their
expression are characterised as follows:
-  two plasmids have been inserted into the same locus in two to five gene copies.Their
presence  has been demonstrated by southern blotting.
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-  the product of the inserted genes, the CRYIA(b) protein (Bt-delta-endotoxin) from
the two genes is expressed  in the leaves and in pollen respectively  but its concentration is
below 5 ppb. However the toxin is apparently  expressed  in the kernel since in a bioassay
study with the European  corn borer, insecticidal  activity was observed in fresh, but not in
dried or re-hydrated  kernels, Phosphinothricin  acetyl transferase (PAT), responsible for the
increased  tolerance to the herbicide glufosinate  ammonium,  was not detectable in kernels,
but traces were found in the plant. On the basis of current knowledge the prokaryotic bla
gene construct (p-lactam antibiotic resistance) would not be expected to be expressed in
the maize plant.
2. Toxicological  assessment
2.1 Products of the cryIA(b) gene encoding Bt-delta-endotoxin:
Both the truncated  maize crylA(b) gene and the native crylA(b) gene produce protoxins which
undergo proteolytic  cleavage  in the mid-gut of insects resulting  in the same active toxin. The
native CRYIA(b) protein and the corresponding  protein from transgenic  maize, have sirnilar
target range effects thereby demonstrating  the likelihood of similar biological properties for
the two proteins.
The native CRYIA(b) protein (65% purity) has been tested for acute toxicity in mice and no
mortality  has been reported  at a dose of 5 g per kg body weight. Furthermore, reports in the
literaturer of a 28 day study with mice on CRYIA(b) protein, did not reveal any mammalian
toxicity at 1.5 g per kg body weight, the only dose level tested. Moreover, it was
demonstrated that CRYIA(b) was rapidly degraded in vitro in sirnulated gastric fluid
containing  pepsin at pH l-1.2. Since the CRYIA(b) product level in kernels is below 5 ppb,
dietary exposure  to CRYIA(b) from maize kernels is expected  to be very low.
2.2Products of the bar gene encoding phosphinothricin  acetyl transferase (PAT)
The enzyme  phosphinothricin  acetyl transferase  (PAT) is not likely to present safety problems.
The quantitative level of PAT in kernels is very low. Its enzymatic function is specific to a
substrate  which is not naturally  present in humans,  namely phosphinothricin, and furtheffnore,
it is degraded and inactivated in simulated gastric fluid containing pepsin at pH l-1.2. It is
therefore  unlikely to retain any enzymatic activity in vivo. Furthermore,  no sequence
homology  between the PAT protein and known toxins has been found. The native PAT
protein (51% purity) has been tested for acute toxicity in mice and no toxicity has been
reported  at a dose of 5 g per kg body weight.
Noteborn  HUB, Kuiper HA 1995: Safety  evaluation  of transgenic  tomatoes expressing B/ endotoxin.
In: Application  of the principles of substantial  equivalence  to the safety evaluation of foods or food
components  from plants  derived by modern biotechnology. Report of a WHO workshop, Copenhagen,
World Health Organisation,  Food Safety  Unit
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3. Nutritional  assessment
The newly expressed proteins have no nutritional significance  and the composition of the
transgenic  maize is within the known biological  variation of the composition  of the host plant.
It is concluded that transgenic maize (event 176) is substantially  equivalent to the
corresponding  non-transgenic  maize from a nutritional point of view.
4. Allergenicity
The Committee expressed an opinion covering general aspects of food intolerance  including
allergenicity  at its 98th Meeting (September 1995).
The amino acid sequences of the proteins CRYIA(b) and PAT do not show any homology
with proteins of known  allergenic potential. Moreover,  the new gene products appear to be
readily degraded by simulated gastric fluid in vitro. Comparison  of the protein profiles of the
transgenic maize and the native maize by SDS gel electrophoresis  and iso-electric focusing
give no indication that the maize protein have been changed.  There are no indications  that the
prolamine  proteins  have been altered which is of relevance for patients with coeliac disease,
but this possibility  cannot  be excluded. It is therefore concluded  that it is unlikely that the
genetic rnodification  changes the potential for allergenicity in the kernel of the transgenic
maize. This does not exclude the possibility  that there will be individuals  allergic to this variant
of maize, just as there are individuals who are allergic to traditionally  produced variants of
maize.
5. Ilorizontal  gene transfer
Studies of the transfer of intact genes from plant materials to micro-organisms  have
demonstrated  an extremely low likelihood  of transfer, suggesting that the probability  of this
event occurring in practice is very small. There is no evidence  that genes from plants have ever
been transferred under natural conditions to bacteria. In addition, the degradation of DNA
occurring during processing of maize and its intestinal passage  reduces this possibility  even
further. Bacteria with natural ampicillin resistance  exist in the environrnent  as well as in human
intestines. Nevertheless,  in the view of the SCF, the acquisition-of additional resistance from
this transgenic maize by intestinal bacteria needed special attention. The Commission
convened an expert consultation on the subject, where SCF and SCAN together posed a
number of questions to the specialised experts. From this consultation  it is confirmed that the
degeneration of DNA through processing of maize and its products and the enzymatic
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decomposition of DNA in the gastrointestinal  tract of man and animal makes the residual
amount of intact DNA which could contain  a gene very small. Furthermore, the probability for
transfer of plant DNA by transformation to bacteria is small,-as is the chance for the
transformed DNA to become  functional in the bacteria. Even if this unlikely sequence of
events, each of which has a very low probability,  were to take place, it would have no
detectable additional  effect as the bla gene is already widely spread in nature including human
and animal gastrointestinal tracts. Should transformed bacteria harbouring  the high copy
plasmid pUCl8 of the transgenic  maize arise, they would not have a competitive advantage
and therefore would not lead to their spread and interference  with therapy by beta-lactam
antibiotics.
6. Assessment of secondary changes
In addition to the products of the inserted genes, a number of comparisons  between the
transgenic  maize plant and the equivalent non-transgenic  plant have been performed. A series
of morphological parameters were examined as well as yield. DIMBOA (2,4- dihydroxy-7-
methoxy-I,4-benzoxazin-3-one),  one of the natural defence compounds of the maize plant
towards, for example, the European corn borer was also examined. No significant differences
in morphology, yield or DIMBOA  content were observed. Differences between the
concentrations  of other components of toxicological or nutritional relevance in the genetically
modified  plant and the parent plant were statistically  significant  in some instances  but, even so,
the measured levels were still within the published  reference biological variation for maize.
Animal feeding studies with the genetically modified maize supported its substantial
equivalence.
Conclusions
On the basis of the information provided  the Committee  draws the following  conclusions;
- The transgenic maize is, except for the inserted traits, substantially equivalent to maize
presently on the market,
- Animal feeding studies with the genetically modified maize support its substantial
equivalence  to the parent plant.
- No nutritional concerns are associated with the use of this transgenic maize.
- It is unlikely that the genetic changes introduce  any new potential for allergenicity.
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- No human toxicological  concerns arise regarding the inserted traits based upon the
toxicological  and degradation data considered.
- The possibility  that the product would add significantly  to the already  widespread occurrence
of ampicillin resistant bacteria in animals  and man is rernote.
The latter conclusion  was based on the balance of evidence available at this time to the
Comrnittee, which derived from theoretical  considerations  and laboratory  studies. A
stepwise assessment regarding  the gene construct itself, its distribution and persistence
in maize and its products, the possibility of its transfer from maize to gram negative
bacteria,  and the possibility that it would function in such bacteria led to the conclusion
that the risk of bacterial transformation  is extremely low.
The Comrnittee was conscious of the general  question of the use of genes coding for antibiotic
resistance in marker gene constructs in the development  of novel foods and proposes to
scrutinise the future needs and application  of marker genes.
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Terms of Reference
To evaluate the safety-in-use of B-cyclodextrin  (BCD) as a carrier  and
by the action of the enzyme cycloglycosyltransferase  (CGTase)
circulans on partially hydrolysed  starch.
stabiliser, manufactured
obtained from Bacillus
Background
BCD is a food additive with potential application as a carrier and stabiliser of food flavours,
food colours and sorne vitamins. It is a cyclic heptamer  composed of seven glucose units
joined "head-to-tai1" by o.-l,4links. It is manufactured  by the action of the enzyme  CGTase
on partially hydrolysed  starch.  JECFA has also evaluated BCD manufactured by the action of
CGTase, obtained from Bacillus macerans,  Bacillus circulans or related strains of Bacillus. on
hydrolysed  starch syrups, in 1993 and 1995 and has allocated an ADI of 0-5 mglkgbw (1,2).
Evaluation
The manufacturing method described in the petition (3) uses a crude CGTase preparation,
which is produced  by heat treatment  of the non-pathogenic  microorganism  Bacillus circulans.
The inforrnation supplied on the process  controls in the manufacturing  process for the enzyme
preparation, on the batch to batch consistency  of the preparation and on its toxicity was
limited (3-6) However, since the final BCD product is processed to a high level of purity
before use and has been subject to extensive toxicological  testing,  the Comrnittee  considered
that the data provided on the enzyme preparation  were suffrcient. However, the Cornmittee
considered that the source of the enzyme used to manufacture  BCD should be cited in the
specification  for BCD.
The metabolism data submitted on BCD are limited, but indicate that, in both animals  and
humans, at low dietary concentrations  BCD is probably  not absorbed  in the stomach or small
intestine, but is degraded in the colon by gut microflora and possibly endogenous enzymic
activity (7-14). There is evidence from a toxicity study in dogs (15-16) that, at a high dietary
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concentration of 5oA BCD, up to 60/o of administered BCD is absorbed and excreted
unchanged  in the urine in this species.
The toxicity studies supplied on BCD manufactured as described in the application  comprise  a
number of in vitro and in vivo mutagenicity studies (17-20), a 13-week study in the rat (21-
22), one-year studies in the rat and dog (15-16, 23), a teratology  study in the rat (24), a
multigeneration  study in the rat (25-26) and chronic toxicity/carcinogenicity  studies in the rat
and mouse (27-28). All studies were conducted and reported to an acceptable standard.
The results of these studies indicate that BCD has little systemic activity in laboratory animals.
In the one-year study in the dog, in which BCD was administered at dietary concentrations  of
0,0.62, 1.25 and 5.0o , the authors identified a No Observed Adverse Effect Level (NOAEL)
of 5Yo BCD in the diet, on the assumption that certain urinary effects reported at this level
were not indicative of systemic toxicity in the absence of adverse  histopathological findings.
The Committee  considered  that, since the kidney is known to be the target organ for
parenterally administered BCD (1) and there is evidence  that BCD is absorbed  at high levels of
administration,SYo  BCD is a minimal effect level and the true NOAEL in dogs is 1.25o/o in the
diet, equivalent to an intake of 466 mglkgbw/day.
In a teratology study, BCD was given by gavage  at doses of 0, 1 .25,2.5 and 5.0 g/kg bw/day
and no adverse effects were observed. In a multigeneration  study, BCD was given at dietary
doses of 0, 1.25,2.5 and 5.0oh. The results indicated  that 1.25o in the diet, equivalent to
around 550-3000 mg/kg bw/day over the different  phases of the study, is a NOAEL for
reproductive effects in the rat. Minor effects reported at higher doses are considered to be
secondary  to mild depression  of food consumption  and body weight gain in the dams. [n view
of the low absorption  of BCD, the Committee  considered that a teratology study in a second
species  was not required.
BCD was negative in in vitro tests for point mutations  in bacterial  and mammalian cells, in an
in vitro test for chromosome  aberrations in human lymphocytes,  and in an in vivo
micronucleus  test. In the chronic toxicity/carcinogenicity  study in the rat, BCD was given in
the diet to provide nominal doses of 0, 25, 75, 225 and 675 mglkg bw/day. In the chronic
toxicity/carcinogenicity  study in the mouse, BCD was given in the diet to provide nominal
doses of 0, 75, 225 and 675 mgkg bw/day. In the mouse BCD caused occasional,  non-
neoplastic lesions in the lower gastrointestinal  tract which were considered by the authors to
be the cause of death in a few mice and to be related to administration of high doses of a
unabsorbed  material. The Committee considered  these lesions to be unusual but of no
significance for humans. The Committee noted that both in the mouse and the rat
carcinogenicity  studies, a few tumour types were of slightly higher incidence in BCD-treated
groups than in concurrent  controls andlor historical controls. However, in the absence of any
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clear dose-related effects, these were judged to be of no toxicological significance.  The
Committee  concluded that BCD showed no carcinogenic potential.
Conclusion
The Committee  considered  that an ADI of 0-5 mglkg bw can be set for p-cyclodextrin,
derived from a NOAEL of 466 mglkg bw/day  in the one-year dog study and a safety factor of
100. This evaluation and ADI applies only to p-cyclodextrin  manufactured  using a CGTase
preparation from Bacillus circulans.
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(expressed  on 13 December  1996)
Mandate
To advise on the nature, the essential compositional
any specific requirements  concerning  the labelling  and
requirements, where necessary,  and
appropriate  use of FSMPs.
1.
Documents consulted
In drafting its opinion the Committee  considered extensively  the relevant Codex
Standard (CODEX STAN 180-1991 on Labelling of and Claims for Foods for
Special Medical  Purposes). It considered  also information on the nature and use of
such products in different Community Member  States provided by the Association
of Dietetic Food Industries of the EU (IDACE).
Background
FSMPs are foods for particular nutritional  uses (dietetic foods) covered by the
framework  directive 89l398lEEC. This latter defines dietetic foods in general and
lays down labelling  requirements for them. It also foresees  the adoption of a
specific directive for FSMPs in which the necessary specific provisions shall be laid
down. The opinion of the Committee  has been requested in order to help the
Commission to develop  such a directive,
At the international level FSMPs are described  in the Codex Alimentarius Standard
as a category of foods for special dietary uses which are specially  processed  or
formulated  and presented for the dietary  rnanagement of patients and may be used
only under medical supervision.  They are intended for the exclusive or partial
feeding of patients with limited or impaired capacity to take, digest, absorb or
metabolize ordinary foodstuffs  or certain nutrients contained therein, or who have
other special medically-determined  nutrient requirements,  whose dietary
management  cannot  be achieved only by modification of the normal diet, by other
foods for special dietary uses, or by a combination  of the two. In addition the
Codex Standard lays down labelling provisions specific to these products.  The
Codex Standard does not lay down compositional criteria for these products.
)
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The above description appears to the Committee a reasonable one. However it is
obvious  that FSMPs  comprise a vast range of products  intended for a variety of
conditions difficult or almost impossible to categorise  accordingly. A broad
distinction can however be made between: (i) products which can be qualified  as
nutritionally complete,  which are formulated and presented as able to cover the
entire spectrum of nutritional requirements, if necessary during prolonged  periods,
whether they constitute the only source of food for patients, are designed  to cover
only part of daily requirements  or to supplement  a diet which is inadequate  and (ii)
products which aim to cover the special requirements of various categories  of
patients, such as those which compensate for an euyme deficiency  (e.g.
phenylketonuria, maple syrup urine disease), or which supplement a nutritional
deficiency or enable the patient to adapt to a particular situation (such as renal
insufficiency)  and which are, in essence, nutritionally incomplete.
Given the nature and the diversity of the products in question the Committee can
understand  why the Codex Alimentarius Standard  does not include provisions for
the composition of FSMPs. Firstly it would be very difficult to establish  such
criteria for such diverse products. Second it would be even more difficult to keep
such criteria under review and up to date. However it may be very useful within
the European union and for the purpose of protecting public health and for avoiding
barriers to trade to refer to what may reasonably be considered as normal
requirements for a number of nutrients,  a concept  which can then be used, where
applicable, to determine  essential compositional  requirements  for some of these
products,  taking into account also their distinction into nutritionally  complete  and
incomplete products.
Classification of foods for special medical  purposes
The Committee fully endorses  the labelling  provisions laid down in the Codex
Standard,  namely that the labelling  mentions  unambiguously whether the product is
supposed or not to be the sole source of energy and nutrients for the patients for
whom it has been conceived, and that there is a prominent warning to consumers if
the product is likely to be hazardous for individuals  for whom it is not designed, as
would be the case of dietetic products with a reduced phenylalanine content intended
for patients suffering frorn phenylketonuria, but which would provoke serious
metabolic disorders if thev were to be consumed bv infants. children or adults in
good health,
7.  The Committee also fully subscribes to the idea that these products are to be used
under medical supervision  and that such a warning should appear on the label.
5.
6.
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However it fears that such mandatory notice might not fully protect consumers from
misuse of some FSMPs.  The Committee  suggests  therefore that the availability or
sale of products likely to be hazardous for persons for whom such products are not
intended  should be restricted to health care services or pharrnacies.
The existence  or not of undesirable  effects and, whether or not the food is able to
cover on its own the energy and nutrient requirements of the patients for whom it
has been designed, should be the criteria which should serve as a basis for
classifying  products and for deciding on the warnings which should be included on
their labels. Consequently,  the Committee recommends distinguishing between:
(t) nutritionally  complete  foods which, if they are consumed  orally or administered
enterally in appropriate quantities cover by themselves the normal nutritional
requirements  of the people of the age group for which the product has been
formulated; these products may be the only source of food for such people,  may
substitute for a part of their diet or be used as supplements;  and
(i1) nutritionally  incomplete foods, whose essential  features of composition  diverge
to a greater or lesser extent from the limits listed in Annex I, whether they are
proposed as the only source of food for the patients for whom they have been
formulated, as a paftial substitute for their diet or as a supplement to their diet;
mixtures of amino acids, whether equilibrated or not, modules which, according to
various combinations (proteins,  lipids, carbohydrates, minerals and vitamins) make
it possible to meet the special nutritional requirements of patients and supplements
of various kinds aimed at the dietetic treatment  of an illness or a specific disorder all
come under this category.
Essential composition criteria of nutritionally
complete foods for special medical purposes
It would be completely unrealistic to want to define the essential composition
criteria of foods designed for special medical purposes to treat specific diseases  or
disorders or formulated  to respond to particular situations, Any attempt  at
harmonization in this area would meet with insurmountable  technical obstacles.
Such a step would also constitute a major stumbling block to innovation.  The
Committee  proposes therefore abandoning this idea, including for foodstuffs
intended  for premature and/or low-birthweigth infants, which are excluded  from the
scope of Directive 9l|3ZIIEEC.
9.
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There would nevertheless be every advantage in defining the composition criteria
for the products under category (i), designed to cover alone or in association  with
others the normal nutritional requirements  of a defined age group. The adoption by
the Member States of individual regulations  would in effect constitute an obstacle  to
the free circulation of such products, whereas nothing would justify such differences
of interpretation  concerning the mineral, vitamin or trace element content of such
products since they are, by definition,  nutritionally complete. An analysis of the
state of this market  reveals that such obstacles do exist nowadays and that. as a
result, it is necessary  to harmonize  the rules.
The nutritional requirements of children over ten years of age, of adolescents  and
adults do not differ in any appreciable way. Therefore,  in order to be sure that the
needs of almost the entire (97.5%) population will be covered, the Committee  has
based its recommendations  for these age groups on the PRIs (Population  Reference
Intakes) of adult males (>18 years), as defined in the report by the Committee  on
Nutrient and Energy Intakes for the European Cornmunity (SCF,31st  series).
These PRIs, divided by 20 to arrive at 100 kcal, assuming 2000 kcal as the average
energy intakes of these age groups, constitute  the minimum values for each vitamin,
mineral and trace element. In the case of nutrients for which PRIs have not yet
been proposed, (i.e. vitamins D, E and K, biotin, pantothenic acid, sodium,
chloride,  magnesium, manganese, chromium, molybdenum  and fluoride),  the
Committee recommends using as a basis, when they exist, the recommended  dietary
allowances  (NAS/NRC RDAs) for men over 18 years of age; the US recommended
dietary allowances  set for vitamins D, E and K were therefore used in this report as
reference values. In other cases, the Committee suggests using as limits the
"acceptable  range of intakes" proposed in the above mentioned SCF report, or in
their absence the "acceptable  range of intakes" proposed in the above mentioned
SCF report, or in their absence the "estimated safe and adequate  daily dietary
intakes"  (ESADDI)  suggested by the Food and Nutrition Board. The "acceptable
range of intakes" for potassium has also been retained in this report, despite the
existence of a PRI, both for reasons of coherence with respect to the other
electrolytes (sodium and chloride) and for the upper safe level of intake for
potassium  (5.9 g/d) recommended by the SCF not to exceed twice the PRI (3.1 g/d)
(Annex  1).
The Committee  also felt that it would be wiser to fix upper limits, too. Indeed,
prolonged excessive intakes could have undesirable  consequences. What is more, if
there were no upper limits, it would not be possible to draw a demarcation  line
between  nutritionally complete foods (category i) and those aimed at covering
special requirements (category ii).  The general rule suggested by the Committee
would be to fix this upper limit to about 3 times (300%) the PRI or, in its absence,
11.
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the RDA, where such values have been defined by the SCF or the NASiNRC
committee.  The Committee appreciates that this approach  is in part arbitrary but it
is felt that this provides a prudent limit above which there would be no nutritional
benefits and which also minimises the risk of toxicity. An exception should however
be made for Vitamin C due to discrepancies  between  the PRI for adults (45 mg/d)
and the minimum value set for infants in the directive 9I|3ZI1EEC (8 mg/100 kcal)
(see below para 13); in that case the upper limit should be fixed to 5 times the PRI.
In the case of nutrients for which only "acceptable  range of intakes" or "safe and
adequate intakes" have been proposed, the upper and lower values should be
retained  as such. However for fluoride, whose addition to these products should not
be compulsory,  only an upper limit should be retained, it being the upper limit of
the NAS/NRC  "safe and adequate intake", divided by 20, given the choice to
express the limits per 100 kcal. Finally where other nutrients not included in Annex
I  were to be included in these products, especially substances considered
"conditionally essential" (e.g., choline, taurine, carnitine, inositol, nucldotides,
etc), their levels should be in line with those to be found in the usual average diet
(cxlNFSDU 96/11).
Nutritionally complete foods for infants and children up to age 10 years
Complete formula foods for infants (0-I2 months) should comply with the
provisions  of the directive gll3zIlEEC  as modified by directive 96l4lEC. In the
absence of rninimum  values for selenium specified in the above directives the
selenium PRI for infants of 6-12 months could serve as basis for their
establishment. The " safe and adequate intakes" for infants of 0-6 months of age
defined by the NAS/NRC could serve as the basis for defining the limits for
manganese,  chromium and molybdenum for which the Committee had considered
that requirements cannot be established reliably. Finally, maximum levels should
be established for all nutrients,  including fluoride, where such maximum  levels are
not stipulated in directive 91,l32LlEEC.  This is the case for all water-soluble
vitamins, vitamin E, vitamin K and iodine. Principles which are analogous to those
defined in  $  12  could be  used for  this  age category, i,e.
3 times the minimum value for the group B vitamins, vitamin C and vitamin E.
The maximum values for vitamins D and K could also be fixed at 3 times the
minimum values given the needs of young infants for these vitamins and the fact
that the maximum  value for vitamin A defined in directive 9ll3?IlEEC is 180 pg
RE, that is 3 times the minimum values of 60 pg RE (Annex II).
14.  The needs of young children and children aged from 1 to 10 years, expressed per
100 kcal, do not differ substantially from those of children above 10 years of age,
13.
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adolescents and adults. Complete formula foods for young children and school-
children (up to age 10 years) should therefore contain per 100 kcal the same
amounts of nutrients as those for adults, except for the following  deviations:
Vitamin D: 1 - 3 pgl100 kcal
Calcium:  50 - 100 mg/100 kcal.
Similar proposals are currently under discussion in the Codex Committee  on
Nutrition and Foods for Special Dietary Uses (CX/NFSDU 96llI).
Disease-specific diets
Complete  special formula foods often differ in only one or a few points - to a
greater or lesser extent - from the composition of a complete  formula food, in order
to respond to disease-specific  requirements.  In these cases, deviations  from the
established  minimum and maximum levels are admissible if  specific dietary
requirements call for adjustments  to be made. As a consequence,  these deviations
should be explicitly stated and the underlying  reasons given (such as no added
vitamin A and lower phosphate and potassium levels for patients with renal
insufficiency).  However, any nutrients  contained in these complete  special diets
that are not subject to disease-specific  adjustments  shall be covered by the same
recommendations  as those applying to complete  formula foods (CX/NFSDU  96/11)'
In accordance with the Committee's conclusions  on the lists of nutrients  and
additives likely to be used in formulating  products for special medical purposes, the
Committee is of the opinion that the future legislation on this subject should provide
the possibility  for manufacturers to use, where necessary, nutrients or additives
which do not feature on their respective positive lists, provided that they can
scientifically justify the reasons for so doing.
16.
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Annex I:
Vitamins:
Vitamin A (pg RE)
Vitamin D (pg)
Vitamin  E (mg a-TE)
Vitamin K (pg)
Vitamin C (mg)
Thiamin  (mg)
Riboflavin (mg)
Niacin (mg NE)
Vitamin BO (mg)
Folic acid (pg)
Vitamin B1p!te)
Pantothenic  acid (mg)
Biotin (pg)
Minerals:
Sodium (mg)
Chloride  (mg)
Potassium  (mg)
Calcium (mg)
Phosphorus  (mg)
Magnesium (mg)
Trace Elements:
Iron (mg)
Zinc (mg)
Copper (mg)
Iodine (pg)
Selenium  (pg)
Manganese (mg)
Chromium  (pg)
Molybdene (pg)
Fluoride  (mg)
"Acceptable range
3-12.
t5 - 100
575 - 3500
575 - 3500
1600 - 5900
150 - 500
l-10
50 - 200*
75-250*
1.5 - 4.0*
n2  Limits/lOO  kcal
35 - 100
0.5 _ 1.5
0.5 - 1.5
3.5 - 10
2.25 - 12
0.06 - 0.18
0.08 - 0.24
0.9 - 2.t
0.08 - 0.24
10-30
0.07 - 0.21
0.15 - 0.6
0.75 - 5
30 - 175
30 - 175
80 - 150
35 - r00
30-80
7.5 - 2.5
0.5 - 1.5
0.5 - 1.5
0.06 - 0.18
6.s - 20
2.5 - 7.5
0,05 - 0.5
2..5 - 70
3.5 - 12
<o.z
Suggested limit values per 100 kcal for vitamins, minerals and trace
elements in nutritionally complete  foods intended for use by children over 10
years of age, adolescents and adults.
PRI/RDAI
700
10*
10*
70*
45
1.1
1.6
18
1.5
200
1.4
700
550
9
9.5
1.1
130
55
Population Reference Intake (PRI) or Recommended Daily Allowances (RDA)*, if no PRI has been
proposed by the SCF (31st series).
"Acceptable range of intakes",  according  to the SCF report (3lst series) or "estimated  safe and
adequate  daily dietary intakes "according  to the 1989 NAS/NRC  report* (RDA,1989)  when  no
"acceptable range" has been proposed by the SCF.
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Annex II: Suggested  limit for vitamins,  mineral and trace elements in nutritionally
complete  foods values per 100 kcal for infants (0-12 months).
Vitamins:
Vitamin A (pg RE)
Vitamine D (pg)
Vitamine  E (mg cx,-TE)
Vitamin K (pg)
Vitamin C (mg)
Thiamin  (mg)
Riboflavin (mg)
Niacin (mg NE)
Vitamin 86 (me)
Folic acid (pg)
Viramin Bp(uE)
Pantothenic  acid (mg)
Biotin (p+g)
Minerals:
Sodium  (mg)
Chloride (mg)
Potassium (mg)
Calcium (mg)
Phosphorus  (mg)
Magnesium (mg)
60 - 180
1-3
0.5 - 1.5
4-12
8 -25
0,04 - 0.12
0.06 - 0.18
0.8 -2.4
0.035 - 0.1
4-12
0,1 - 0.3
0.3 - 0.9
1,5 - 4.5
70-60
50 - 125
60 - 145
50-1251
25 -90
5-15
0.5 - 1.s
0.5 - 1.5
20-80
5-15
r -3
0.05 - 0.1
z-8
3-6
< 0.2
Trace elements:
Iron (mg)
Zinc (mg)
Copper  (pg)
Iodine (pg)
Selenium  (pg)
Manganese (mg)
Chromium  (pg)
Molybdene (pg)
Fluoride  (mg)
I The calcium/phosphorus ratio shall not be less than 1.2 nor greater than 2.0
ScientificCommittee for f,'ood (f,'ofiy-F irst Series)OPINION ON THE SAFETY IN USE OF
KOI\JAC GUM AS A FOOD ADDITTVE
(expressed on 13I)ecember 1996)
Terms of reference
The Cornmittee was asked to consider the safety-in-use of Konjac gum as food additive.
Background
Konjac gum is a water-soluble hydrocolloid  obtained from the root of the perennial plant
Amorphophallus konjac which is cultivated in Asian countries. It has been used for centuries
as a traditional foodstuff in Far East countries, for example in Japan and China, in the pro-
duction of gels and noodles. According to the petitioner, the term Konjac gum is used for a
refined product and corresponds to the material  evaluated by JECFA under the name Konjac
flour (1)
The table below shows the major parameters of the specifications of Konjac gum:
Ether-soluble  materialnot more than 0.1 %
Water-soluble  fibres
Moisture
Starch
Protein
Ash
Arsenic
Lead
Total heavy metals
Viscosity (1% solution)
Salmonella
Escherichia coli
not less than75  o/o
not more than 12Yo
not more than3 
o/o
not more than3 Yo
not more than 5.0 o/o
not more than 3 ppm
not more than 2 ppm
not more than 10 ppm
at least 3000 cps
negative
not more than 3 mpr/g
The main component  is the water-soluble  high-molecular-weight  polysaccharide gluco-mannan
which consists of D-mannose  and D-glucose units at a molar ratio of 1.6:1.0, connected by
B(l-a)-glycosidic  bonds. Shorter side chains are attached  through  B(l-3)-glycosidic  bonds, and
acetyl groups occur at random at a ratio of about I group per 9 to 19 sugar units. The
molecular weight of glucomannan  ranges from 200.000 to 2.000.000 dalton. Minor
components are insoluble fibres, starch and proteins, which have not been further specified (2,
3)
Konjac gum has been proposed for use as gelling agent, thickener, emulsifier  and stabilizer  rn
foodstuffs, for example pasta, baked goods, sausages, salad dressings, ice creams, des-serts,
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jams, mayonnaise, soups and beverages. It is intended to be used at levels ranging between
0.02 and 1.0 % (2) The anticipated maximum intake from food additive  uses was estimated to
be about 3 g/person/day.  When consumed  in traditional food in Japan and China, intakes may
be up to 4 glpersor/day  (1).
Toxicological  evaluation
The available toxicity data on Konjac gum/flour (specifications not given in most cases)
include data from an acute oral toxicity study in rats, a study on skin sensitization  in guinea
pigs (Buehler test), sub-acute  and sub-chronic feeding  studies in rats addressing specific
questions  e.g. effects on intestine, colonic microflora and protein absorption, an 18-month
study with rats performed  to examine the effect on cell-ageing,  and an embryotoxicity  study
with domestic  cats (2, 4-8). None of these studies indicated any relevant toxic effects. The
observed reduction in body weight, and caecum/colon  enlargement  are typical of the admi-
nistration  of high doses of non-digestible,  non-absorbed, high-molecular-weight materials,  e.g.
cellulose, pectin or guar gum. The sfudies,  however,  can not be regarded as adequate in terms
of modern standards.  They do not allow to derive a no-effect  level,
Genotoxicity tests with Konjac gum/flour  (Ames test, mouse lymphoma assay, mouse bone-
marrow  micronucleus test) were negative (2).
According to published  data, studies in humans with Konjac flour did not reveal any toxic
effects. Only diarhoea,  flatulence and slight abdominal pain have been reported  at high doses.
Limited human studies suggest that these effects on the gastrointestinal  tract occur with single
doses in excess of about 5 g/person/day (9) In addition, a reduction of the absorption of fat-
soluble vitamins E and A has been reported.  The absorption of water-soluble  vitamins  Brz and
81, r€spectively, was not or only slightly  influenced (10, 11). There was no influence  on
mineral absorption.  Some findings suggested  a positive influence on human health, for
example  reduction of the gastrointestinal  transit time, body weight and blood lipid levels,
effects which are also observed  after the ingestion of other types of dietary fibres.
The main component  glucomannan  seems to be non-digestible  by human intestinal enzymes,
but is susceptible to digestion  by enzymes of the colonic microflora. It has not been clearly
demonstrated, however, to what extent the material is decomposed in the intestine.
Seven cases of oesophageal obstruction  caused by the swelling of tablets containing  non-
hydrated glucomannan after ingestion  were reported from Australia where the substance has
been marketed as a dietary aid. However,  no cases of oesophageal obstruction  caused by
hydrated Konjac materials have become  known (12).
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Conclusion
The toxicological data on Konjac gum are insufficient to establish an ADI Adequate sub-
chronic and long-term feeding  studies with this material are lacking and a no-observed-effect
level can not be derived. In addition, it has not been clarified to what extent the main
component glucomannan is digested in the human  intestine.
On the other hand, the existing data (including genotoxicity studies) as well as human
experience do not give reason for concern. Konjac materials have a long history as tradi-tional
food in Far East countries. Apart from diarrhoea,  abdominal  pain and an effect on vitamin
absorption after ingestion of high doses, no adverse effects of oral ingestion  have been
reported in humans.
The Committee considers that the use of Konjac gum as an additive at the intended levels up
to 7o/o in food is acceptable provided that the total intake from all sources did not exceed
3 gld This upper limit should be taken into account when setting the conditions  of use.
The Committee notes that directive 95/2lEC  includes  a footnote in relation to similar pro-
ducts which points out that these substances should not be used to produce  dehydrated
foodstuffs  intended to rehydrate on ingestion (13). The Committee considers that a similar
remark would be applicable to Konjac gum.
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Terms of reference
The Committee was asked to consider the safety-in-use  of Konjac glucomannan as food
additive.
Background
Konjac glucomannan  is a water-soluble hydrocolloid  obtained from Konjac flour by washing
with water-containing ethanol. Konjac flour, the unpurified raw product isolated frorn the root
of the perennial plant Amorphophallus konjac, has been used for centuries  as a traditional
foodstuff in Far East countries, for example in Japan and China, in the production of gels and
noodles.
The table below shows the major parameters  of the specifications of Konjac glucomannan:
Total dietary fibre  not less than 95 o/o (on a dry weight basis)
Loss on drying  not more than 8 o/o
Ash  not more than2o/o
Protein  not more than 1.5 o/o
Starch  not detected (detection limit ?)
Ether-soluble  material  not more than0.5  Yo
Arsenic  not detected (detection limit 0.2 pprn)
Heavy metals  not detected (detection limit I ppm)
Sulfite  not more than 4 ppm
Chloride  not more than 0.02 Yo
50 o Alcohol-soluble material  not more than?o/o
Viscosity (1 % solution)  not less than 60 000 cps
Salmonella  negative
Escherichia coli  negative
The main component glucomannan  is a water-soluble high-molecular-weight polysaccharide
consisting  of D-mannose  and D-glucose at a molar ratio of 1.6:1.0, connected by B(1 -4)-gly-
cosidic bonds with a branch at about each 5Oth or 60th unit. About each 20th sugar residue is
acetylated. The molecular weight ranges from about 500.000 to 2.000.000 dalton. Minor
components are insoluble fibres, proteins  and lipids, which are not further specified (1,2).
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Konjac glucomannan  has been proposed for
emulsifier,  stabilizer  and gelling agent in baked
soups.
use in foodstuffs, for example as thickener,
goods, fish and meat products, pasta, jam and
It is intended to be used at levels ranging between 0.01 and 2 o/o depending  on the food-stufi
and a daily intake of approximately  49 is considered realistic  by the producer (l)  :that is the
same intake reported for Konjac flour which can be reached by traditional use (3).
Toxicological  evaluation
The available  toxicity data on Konjac glucomannan  include data from acute oral toxicity
studies in mice and rats, a study on skin sensitization  (guinea pig maximization test), a sub-
acute feeding study (28 days) in rats and sub-chronic feeding studies (90 days) in beagle dogs
and rats, the latter combined  with a study on reproduction  toxicity (1, 4-6). The 90-day
studies did not reveal relevant toxic effects. Reduction  in food consumption  and body weight
and caecum/colon  enlargement are commonly  observed in feeding  studies with non-digestible
dietary fibres and were found as well as some changes in hematological  and clinical chemical
parameters only at high doses. The no-observed-effect level (NOEL) was 2.5 o/o Konjac
glucomannan in the diet, corresponding to |.25 g/kg body weight/day.
Genotoxicity tests in bacteria (Ames test and gene mutation assay with E.coli) were negative
(7)
According  to published  data on Konjac flour, studies in humans did not reveal any toxic
effects. Only diarrhoea, flatulence and slight abdominal pain have been reported at high doses.
Limited human studies suggest that these effects on the gastrointestinal  tract occur with single
doses in excess of about 5 g/person/day (8) In addition, a reduction of the absorption of fat-
soluble vitamins E and A has been reported.  The absorption of water-soluble  vitamins  B12 and
81, resp€cti,r*1y,  was not or only slightly  influenced (9, 10). There was no influence on mineral
absorption.  Some findings suggested a positive influence on human health, for example
reduction  of the gastrointestinal  transit time, body weight and blood lipid levels, effects which
are also observed  after the ingestion of other types of dietary fibres.
The main component,  glucomannan,  seems to be non-digestible  by human intestinal enzymes,
but is susceptible to digestion  by enzymes of the colonic microflora. It has not been clearly
demonstrated, however, to what degree the material is decomposed in the intestine.
Seven cases of oesophageal obstruction  caused by the swelling of tablets containing  non-
hvdrated glucomannan after ingestion were reported from Australia where the substance has
been marketed as a dietary aid. HoweverT no cases of oesophageal obstruction  caused by
hydrated Konjac materials have become  known (11).
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Conclusion
Konjac glucomannan  was tested adequately in 90-day feeding studies with rats and beagle
dogs. These studies did not reveal any relevant toxic effects and a no-observed-effect  level of
2.5oA glucomannan in the diet can be derived,  corresponding  to 1.25 glkg bodyweight/day.
However, a long-term toxicity/carcinogenicity  study is lacking and only gene mutation tests in
bacteria were performed  with a negative result. In addition, it has not been clarified to what
extent the glucomannan  is digested in the human intestine. Therefore an ADI can not be
established.
On the other hand, the existing experimental  data as well as human experience do not give
reason for concern. Konjac glucomannan is consumed as a component  of Konjac flour in Far
East countries where the Konjac materials have a long history as traditional food. Apart from
diarrhoea, abdominal pain and an influence on vitamin absorption  after ingestion of high doses
of Konjac materials, no adverse effects have become  known from studies in humans.
Therefore, the Committee  considers  that the use of Konjac glucomannan as an additive up to I
% in food is acceptable provided that the total intake from all sources did not exceed 3 gld.
This upper limit should be taken into account when setting the conditions  of use.
The Committee  notes that directle 95/2/EC  includes a footnote in relation to similar products
which points out that these substances  should not be used to produce dehydrated foodstuffs
intended to rehydrate on ingestion (12). The Committee  considers  that a similar remark would
be applicable to Konjac glucomannan.
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FIN-001 01 HelsinkVHelsingfors
P./tfn  (358-9) 121 41
F./fax  (358-9) 121 44  35
E-mail:  akatilaus  @ stockmann.mailnet.fi
URL:  http://booknet.cultnet.fi/akMndex.htm
Mllbr Dlstrlbutor!  Ltd
Malta lntemational Airport
PO  Box  25
LQA  05 Malta
Tel. (356)  66  44  88
Fax (356)  67  67  99
Aru Polona
Krakowskie Paedniescie  7
Skr.  pocztowa l0Ol
PL-00-950  Warszawa
TeL  (48-22\ 826 12 01
Fax @8-221 826  62  40,  826 53 34,  826 86 73
E-mail:  arsJrol  @ bevy.hsn.com.pl
ROMANIA
Euronredla
Str.  G-ral Berthelot  Nr  41
RO-70749  Bucuresti
T6l. (40-1 ) 210  44  01 ,61 4 06 64
Fax  (40-1)  21O  44 01,3'12 96 46
PSl.lapan
Asahi Sanbancho Plaza  #206
7-1 Sanbancho,  Chiyoda-ku
Tokyo 102
Tel. (81-3)  32 34 69 21
Fax (81-3)  32  34 69 15
E-mail:  psijapan  @ gol.ccn
U BL: htp://www.psi-japan. com
EBIC Malaysh
Level  7, Wisma Hong Leong
18 Jalan  Perak
50450 Kuala Lumpur
Tel. (60-3)  262  62  98
Fax  (60-3)  262  61  98
E-mail:  ebic-kl  @ mol.net.  mv
PHILIPPINES
Mundl  Prenra  Llbror, SA
Castell6,37
E-28001  Madrid
Tel. (34-1)  €1 33 99
Fax  (34-1)  575  39  98
E-mail:  libreria  @ mundiprensa.es
U R L: http//mtw.  mundiprensa.es
Boletin  Oflclal  dsl  Estado
fralalgar,2T
E-28010  Madrid
Tel.  (34-1)  538  21 1 1 (Libros)/
3U 17  15 (Suscripciones)
Fax  (34-1)  538  21 21 (Libros)/
3U 17  14 (Suscripciones)
E-mail:  webmasler@  boe.es
URL:  htto://www.  boe.  es
BTJ AB
Traktorv6gen 11
5-221 82  Lund
Tln (46-46) 18000o
Fax  (4646)  3079  47
E-post  btjeu-pub@b$.se
URL:  http://www.btj.se/mecla/eu
Slovak  Centre ol Sclentlflc  and Technlcal
Informatlon
NAmestie  slobody 19
SK-81223 Bratislava  1
Tel. (421-7\ 531  83 64
Fax  (421-71531 83 64
E-mail:  europ  @ tbb  1 .sltk.stuba.sk
EBIC Phlllppinet
19th  Floor,  PS  Bank  Tower Sen.
Gil J. Puyat  Ave. cor.Tindalo St.
Makati  CiW
Metro  Ma.iilla
Tel. (63-2)  7s9 66  80
Fax  (63-2)  759  66 90
E-mail:  eccpcom  @ globe.com.ph
UNITED  KINGDOM
The Statlonery  Ofilce  Ltd
Intemational  Sales Agoncy
51 Nine Elms  Lane
London  SWB  sDR
Tel. (44-171)  873  90  90
Fax  (44-171)  873  84 63
E-mail:  jill.speed  @ theso.co.  uk
URL:  httpr//www.the-stationery{ffice.co.  uk
Gospodarekl  v$tnlk
Zalozniska skupina  d.d.
Dunajska  cesta 5
SLO-100O  Llubljana
Tel. (386)  61 1 33 03 s4
Fax  (386)  611 33 91 28
E-mail:  belicd@gveshik.si
URL:  htp://www.gvestnik.si
ccEc
60-letiya Oktyabrya Av.  9
117312  Moscow
Tel. (70-95) 1355227
Fax (70-95) 1355227
SOUTH AFRICA
Joumal  ofilclel
Service  des  publications  des  CE
26,  rue Desaix
F-75727  Paris  Cedex 15
T6l.  (33) 140 5877  O'U31
Fax  (33)  140 58 7/ 00
Bokabud  Larurar  Bl6ndal
Sk6lav6rdustig,  2
lS-101 Reykjavik
Tel. (3s4) s51 s6 50
Fax  (354)  5s2  55 60
D0nya Infotel  AS
lstiklAl  Cad. No:469
TR-80O50  T0nel-lslanbul
Tel. (90-212)  251  91 96
Fax  (9O-212)  251 91 97
Safto
Sth Floor  Export  House,
CNR Maude  & West  Streets
PO  Box 782706,
2146  Sandton
TeL  (27-'11)  883  37 37
Fax  (27-1  1 ) 883  65  69
SOUTH KOREA
Govemment  Suppllec  Agcncy
Publications  Seclion
4-5  Harcourt  Road
Dublin  2
Tel. (353-1)  661  31 1 1
Fax  (353-1 ) 475 27 60
NIG lnlo A/S
Ostenjoveien 18
Boks  6512 Etlerstad
N-06O6  Oslo
rer (7-22197 45 00
Fax  (47-22)  97 45 45
Huntor  Publlcatlonr
PO  Box  404
31 67 Abbotsford, Vicloria
Tel. (61-3)  94 17 sg  61
Fax  (6'l-3) 94 19 71  54
Kyowa  Book  Company
'| F1 . Phyung  Hwa Bldg
41  1-2 Hap  Jeong Dong,  Mapo  Ku
121-220  Seoul
Tel. (82-2)  32267  8Ol1
Fax (82-2)  322  67  82
E-mail:  kyowa2  Q ktnet.co.  kr.
AUSTRALIA
Llcora  SpA
Via Duca  di Calabria, 1/1
Casella  postale  552
l-50125  Firenze
Tel.  (39-55)  64 s4 1s
Fax  (39-55)  U 12 57
E-mail:  licosa  @ flbcc.it
URL:  http//www.ftbcc.Micosa
osEc
StampferbachstraBe  85
CH-8035  Z0rich
Tel. (41-1)  365  53 15
Fax (41-1)  365  54 11
E-mail:  uleimbacher@  osec.ch
U RL:  htp:/Alttw.osec.ch
Subscriptions  only/Uniquement abonnemenE:
Renouf  Publlehlng  Co. Ltd
5369  Chemin  Canotek Road Unit 1
KlJ 9J3  O{lawa,  Ontario
Tel. (1€13)745  26 65
Fax  (1€13)  745  76 60
E-mail: renouf  @ tox.  nsln.ca
U RL:  htp://www.renoubooks.com
EBIC  Thalland
Vanissa Building 8th  Floor
29  Soi  Chidlom
Ploenchit
10330  Bangkok
Tel. (66-2)  655  06  27
Fax (6S2) 655 06  28
E-mail:  ebicbkk  @ kscl 5.th.com
LUXEMBOURG UNITED  STATES OF AMERICA
ilesragsrlos du llvn SABL
5, rue  Raiffeisen
L-241 1 Luxembourg
T6r. (3s2)  40 10 20
Fax  (352)  49  06 61
E-mail:  mdl@pt.lu
Abonnements:
Itessagerlec  Paul Kraur
11, rue Christophe  Planlin
L-2339  Luxembourg
T6r. (3s2)  49 98  88-8
Fax  (352)  49 98 88-444
E-mail:  mpk@pt.lu
URL:  http'//www.mpk.lu
Europrss-Euromedla Ltd
59,  Bld  Vitosha
BG-1000  Sotia
Tel. (359-2)  980 37 66
Fax  (359-2) 980  42 W
CES'KA  REPUBLIKA
NIS  CR - 
prodelna
Konviktskd  5
CZ-1 13 57 Praha 1
Tet.  (42o-2)  24 22 94 33,24  23 09 07
Fax  (420-2124 229.  33
E-mail:  nkposp@dec.nis.cz
UFIL: htlp:/Arrrwv.nis.cz
The lllddb  East Obrrver
41 , Sherif  Streel
Cairo
Tel. (20-2)  393  97 32
Fax  (20-2)  393  97  32
Baman  Asroclatos
461 1-F Assembly Drive
MD20706 Lanham
Tef  . (800)  274  44 47 (toll  lree telephone)
Fax  (8OO)  865 34  50 (tollfree  fax)
E-mail:  query@beman.com
URL:  htp:/Amrw.beman.com
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Pavla  Hatza  1
HB-10000 Tagreb
Tel. (385-1)  /t3  03 92
Fax  (385-1)  43  03  92
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